Measuring the Beat: 57 Stocks Surpassing Earnings Expectations
Academic research has consistently found that corporate earnings surprises cluster around small positive values, rather than large outperformance.
Regeneron Pharmaceuticals Inc. (REGN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bronte Capital John Hempton | 162,618 | $101,398,828 | -6% | 10.89% |
| 2. | 68,600 | $42,774,844 | 4.59% | ||
| 3. | Lee Munder Capital Group Lee Munder | 36,837 | $22,969,343 | -6% | 1.23% |
| 4. | Ranmore Fund Management Sean Peche | 30,000 | $18,706,200 | 2.07% | |
| 5. | Walleye Capital Will England | 22,596 | $14,089,510 | +462% | 0.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $487.01 | 2,557 | $1,245,286.62 | 23,880,537 | 2017-08-25 | Filing | |
| $485.99 | 2,681 | $1,302,949.65 | 23,877,980 | 2017-08-25 | Filing | |
| $485.28 | 5,723 | $2,777,256.30 | 23,875,299 | 2017-08-25 | Filing | |
| $484.21 | 2,000 | $968,420.00 | 23,869,576 | 2017-08-25 | Filing | |
| $482.87 | 4,485 | $2,165,687.20 | 23,867,576 | 2017-08-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $650.15 | 200 | $130,030.00 | 17,303 | 2026-07-02 | Filing | |
| $714.13 | 2 | $1,428.26 | 17,503 | 2026-05-01 | Filing | |
| $712.09 | 1 | $712.09 | 17,505 | 2026-05-01 | Filing | |
| $711.49 | 5 | $3,557.45 | 17,506 | 2026-05-01 | Filing | |
| $710.87 | 2 | $1,421.74 | 17,511 | 2026-05-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 758,492 | $472,950,278 | 0.08% | |
| 2. | 460,602 | $287,203,770 | 0.35% | |
| 3. | 363,479 | $227,370,654 | 0.19% | |
| 4. | 346,637 | $216,142,066 | 0.07% | |
| 5. | 282,199 | $175,962,364 | 0.1% |
News See All
Disappointing Trial Results Hurt Regeneron Pharmaceuticals (REGN) in Q2
Longleaf Partners, managed by Southeastern Asset Management, released its second-quarter 2026 investor letter for its “Partners Fund”. A copy of the letter can be downloaded here.
Is Regeneron Pharmaceuticals, Inc. (REGN) Stock Still a Biotech Leader After Analyst Price Target Cut?
TheFly reported on July 6 that HSBC reduced its price target on REGN to $800 from $990 while maintaining a Buy rating on the shares.
10 Best Innovative Healthcare Stocks to Buy Now
The U.S. healthcare sector has lagged behind the entire market for three consecutive years, with returns of just 0.3% in 2023, 0.9% in 2024, and 12.5% in 2025.
RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) - Here's Why
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc.
10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds
On June 9, Reuters reported that Philips' Future Health Index survey concluded that artificial intelligence improved clinical accuracy and increased patient capacity.
10 Best Non-Tech Stocks to Buy According to Analysts
On June 24, Tom Lee, Head of Research at Fundstrat Global Advisors, appeared on CNBC to talk about how the semiconductor selloff is a buying opportunity, earnings growth is supporting higher stocks, and...
Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy Now?
Is REGN a good stock to buy? We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on r/investing_discussion by Variant_Invest.
Regeneron's (REGN) Antibody Therapy Gains WHO Support During Ebola Outbreak
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best healthcare stocks to buy with highest upside potential. Regeneron Pharmaceuticals, Inc.
10 Best Healthcare Stocks to Buy with Highest Upside Potential
On June 1, Tom Lee, Fundstrat managing partner and head of research, and Fundstrat Capital CIO, appeared on CNBC’s ‘Squawk Box’ to talk about the latest market trends, the market outlook, and more...
Hedge Fund Resource Center